Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Famitinib with Chemotherapy in Early-Stage TNBC
NCT05862064Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Jun 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, famitinib in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Jun 2023; status: recruiting.
02
Drugs
camrelizumabfamitinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05862064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862064.